 |
Advertisement:
Pharmaceutical Technology Drug Delivery Guides
A three-volume set of drug delivery system handbooks. A compilation of articles on methods and processes of manufacturing and administering pharmaceutical compounds to achieve therapeutic effects.Topics include the development of controlled-release formulations and reformulating injectable drugs for oral delivery.
Click here |
|
|
 |
 
|
 |
|
|
 |
 |
Pharmaceutical Technology and D&B Launch Business Marketplace
Pharmaceutical Technology has joined with Dun & Bradstreet Credibility Corp. to launch the Pharmaceutical Technology and BioPharm International Marketplace.
FDA Creates Partnership to Battle Anti-Malaria Counterfeit Drugs
FDA has announced plans to use a new anticounterfeiting tool to detect fake medicines.
Advertisement:
FREE WHITEPAPER: The Key to Tableting Success
Learn about common pitfalls, critical questions to ask your tooling provider, and the basics of tool steel selection.
 Learn More! |
EMA Upgrades Database to Strengthen Supply Chain Security
EMA has upgraded its EudraGMP database to include information on GDP in addition to GMP. The new EudraGMDP database is a key deliverable of the Falsified Medicines Directive that came into effect in January 2013.
FDA Releases Draft Guidance on Labeling Safety
FDA has issued a draft guidance intended to help minimize medication errors.
Advertisement:
Trends in safe handling of potent compounds in pharmaceutical manufacturing processes
Live Webcast: Wednesday, May 15, 2013 at 11:00 AM EDT.
Register Free at
 www.pharmtech.com/trends
|
Lundbeck Launches Selincro as First Alcohol Dependence Drug in Europe
Lundbeck has launched Selincro in Norway, Finland, Poland, and the Baltic countries of Latvia, Lithuania, and Estonia for the treatment of alcohol dependence in patients with high-risk drinking levels.
Report from Thailand
The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.
Advertisement:
Cleaning Validation: Science, Risk, and Novel Approaches to Testing
Live Webcast: Tuesday, June 4, 2013 at 11:00 am EDT.
Register Free at
 www.pharmtech.com/testing
|
Report from Russia
Strengthening government control or striving for compliance with international standards?
|
|
 |
- AstraZeneca and BIND Therapeutics have formed a strategic collaboration to develop and commercialize BIND’s Accurin, a targeted and programmable cancer nanomedicine, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca. The agreement came after data suggested that nanomedicines such as Accurins could selectively accumulate in diseased tissues and cells, leading to higher drug concentrations at the site of the tumor and more importantly, reduced exposure to healthy tissues.
Read More.
- BioOutsource, a contract testing services provider to the biopharmaceutical industry, has opened a new facility in Cambridge, Massachusetts. The facility marks the company’s first North American offices, which were opened in response to increasing demand for the company’s bioanalytical and biosafety services, particularly in the field of biologic and biosimilar characterization. Read More.
- Catalent Pharma Solutions, a provider of drug and biologic development services, delivery technologies and supply solutions, has officially opened a new biomanufacturing center of excellence in Madison, Wisconsin. The facility, which was constructed in response to customer demand, is expected to quadruple Catalent’s current biologics manufacturing capacity and extensively utilize single-use technology for greater flexibility and efficiency. Read More.
- UK-based Malvern Instruments and Germany-based Netzsch Grinding & Dispersing have entered into a cooperative marketing agreement for a broad range of market sectors, including pharmaceuticals. The global agreement, initially in place for three years, will harness the strength of each company’s brands and unique expertise in materials processing and materials characterization.
Read More.
- PerkinElmer will collaborate with the National Center for Drug Screening to advance personalized medicine and drug profiling in China. The two organizations will share knowledge, expertise, and innovative capabilities to establish a personalized drug research and development platform that will validate biomarkers for individualized disease treatment for Chinese patients. Read More.
|
|
Advertisement:
New Strategies for Evaluating Biopharmaceutical Stability
Live Webcast: Thursday, May 9, 2013 at 2:00 pm ET.
Register Free at
 www.pharmtech.com/biostability
|
|
|
|
|
|
|
What has been the most significant benefit of applying quality-by-design (QbD) principles?
|
|
|
|
Contact Us
Click here to contact editorial.
Click here to contact sales. |
|
|
